Casi pharmaceuticals announces third quarter 2024 business and financial results

Beijing, china / accesswire / november 15, 2024 / casi pharmaceuticals, inc. (nasdaq:casi) ("casi" or the "company"), a cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended september 30, 2024. dr. wei-wu he, chairman and ceo of casi, said "the third quarter of 2024 marks a period of substantial progress for casi as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases.
CASI Ratings Summary
CASI Quant Ranking